Marijuana extract reduces seizures in patients with Lennox-Gastaut Syndrome in clinical trial.

GW Pharmaceuticals, the maker of a marijuana-based drug used to help children with rare forms of epilepsy, announced successful clinical trials of the drug Epidiolex in the treatment of Lennox-Gastaut Syndrome (LGS).

Epidiolex is made from pharmaceutical-grade cannabidiol (CBD) oil, a nonpsychoactive compound extracted from the cannabis plant.

In this randomized, double-blind, placebo-controlled Phase 3 clinical trial of the drug, Epidiolex was found to successfully reduce seizures in patients with LGS, a rare and severe form of epilepsy that develops in childhood.

Click here to read the complete article

Emily Gray Brosious ~ ~

Recent News Articles

Friday April 26

Lawmakers Want Legal Protections For Universities That Research Marijuana - Cannabis News

in Law & Crime

by Bruce Kennedy - Editor in Chief

A bipartisan group of lawmakers on Capitol Hill is asking House leadership to protect universities…

1787 hits

Friday April 26

Hemp cultivation wins approval in Connecticut Senate - Cannabis News

in Cannabis News

by Bruce Kennedy - Editor in Chief

Connecticut farmers are one step closer to joining the burgeoning hemp industry after the Senate…

2457 hits

Friday April 26

Jobs in pot are at an all-time high, but the boom is causing rifts in…

in Finance

by Bruce Kennedy - Editor in Chief

Jobs in pot might be at an all-time high, according to a new report.

2160 hits

Friday April 26

How Marijuana Works To Help Those With Multiple Sclerosis - Cannabis News

in Medical News

by Bruce Kennedy - Editor in Chief

In double-blind, placebo controlled trials, MS patients who use cannabis oil, synthetic THC, or an…

2239 hits

Monday April 29

Maine’s marijuana dilemma: ‘Cannabiz’ poised to grow, but in a holding pattern - Cannabis News

in Finance

by Bruce Kennedy - Editor in Chief

Maine has no legal market for recreational cannabis, more than two years after it became…

899 hits